http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
An Improved Single Switched Post Regulator for Multiple Output Isolated Converters
Sang-Gab Park,Seung-Hee Ryu,Kwang-Seung Cho,Byoung-Kuk Lee 전력전자학회 2015 ICPE(ISPE)논문집 Vol.2015 No.6
This paper presents a new high accurate single switched post regulator with voltage-doubler characteristic. The proposed post-regulator requires only one auxiliary switch compared to the bulky and expensive non-isolated DC/DC converter. Moreover, the added voltage-doubler can tightly regulate the slave output current. In addition, the proposed post-regulator can improve EMI characteristics and reduce switching losses due to the ZCS operation of all power switches. Finally, in order to verify the validity of the proposed converter, experimental results from a prototype applicable to the 48” LED 3D TV power supply are presented.
Forced Expression of HoxB4 Enhances Hematopoietic Differentiation by Human Embryonic Stem Cells
Gab Sang Lee,김병수,Jae-hung Sheih,Malcolm Moore 한국분자세포생물학회 2008 Molecules and cells Vol.25 No.4
HoxB4 has been shown to enhance hematopoietic engraftment by hematopoietic stem cells (HSC) from differentiating mouse embryonic stem cell (mESC) cultures. Here we examined the effect of ectopic expression of HoxB4 in differentiated human embryonic stem cells (hESCs). Stable HoxB4-expressing hESCs were established by lentiviral transduction, and the forced expression of HoxB4 did not affect stem cell features. HoxB4-expressing hESC-derived CD34+ cells generated higher numbers of erythroid and blast-like colonies than controls. The number of CD34+ cells increased but CD45+ and KDR+ cell numbers were not significantly affected. When the hESC derived CD34+ cells were transplanted into NOD/SCIDβ2m-/- mice, the ectopic expression of HoxB4 did not alter their repopulating capacity. Our findings show that overexpression of HoxB4 in differentiating hESCs increases hematopoietic colony formation and hematopoietic cell formation in vitro, but does not affect in vivo repopulation in adult mice hosts.
Lee, Jun-Hee,Lee, Ju-Mong,Kim, Joon-Kyum,Ahn, Soon-Kil,Lee, Sang-Joon,Kim, Mie-Young,Jew, Sang-Sup,Park, Jae-Gab,Hong, Chung-Il The Pharmaceutical Society of Korea 1998 Archives of Pharmacal Research Vol.21 No.5
We developed a novel water-soluble camptothecin analobue, CKD602, and evaluated the inhibition of topoisomerase I and the antitumor activities against mammalian tumor cells and human tumor xenografts. CKD602 was a nanomolar inhibitor of the topoisomerase I enzyme in the cleavable complex assay. CKD602 was found to be 3 times and slightly more potent than topotecan and camptothecin as inhibitors of topoisomerase, respecitively. In tumor cell cytotoxicity, CKD602 was more potent than topotecan in 14 out of 26 human cancer cell lines tested, while it was comparable to camptothecin. CKD602 was tested for the in vivo antitumor activity against the human tumor xenograft models. CKD602 was able to imduce regression of established HT-29, WIDR and CX-1 colon tumors, LX-1 lung tumor, MX-1 breast tumor and SKOV-3 ovarian tumor as much as 80, 94, 76, 67, 87% and 88%, respectively, with comparable body weight changes to those of topotecan. Also the therapeutic margin (R/Emax: maximum tolerance dose/$ED-{58}$) of CKD602 was significantly higher than that of topotecan by 4 times. Efficacy was determined at the maximal tolerated dose levels using schedule dependent i.p. administration in mice bearing L1210 leukemia. On a Q4dx4 (every 4 day for 4 doses) schedule, the maximum tolerated dose (MTD) was 25 mg/kg per administration, which caused great weight loss and lethality in <5% tumor bearing mouse. this schedule brought significant increase in life span (ILS), 212%, with 33% of long-term survivals. The ex vivo antitumor activity of CKD602 was compared with that of topotecan and the mean antitumor index (ATI) values recorded for CKD602 were significantly higher than that noted for topotecan. From these results, CKD602 warrants further clinical investigations as a potent inhibitor of topoisomerase I.
Biochemical Properties of a Chitin-Binding Class III Chitinase in Pumpkin Leaves
Lee,Sang Yeol,Kim,Min Gab,Lee,Ji Yeun,Jang,Ho Hee,Lee,Kyun Oh,Kim,Sun Chang The Korea Science and Technology Center 1999 BMB Reports Vol.32 No.6
When we compared the chitinase activity of various plant sources using colorimetric or active gel-staining assay methods, the specific activity of pumpkin leaves was the highest among the samples we analyzed. The highly active chitinase from pumpkin leaves (designated PL-ChtIII) was purified to homogeneity using affinity chitin gel and HPLC Mono-Q anion-exchange cloumn chromatographies. In contrast to other members of the class III chitinase family, PL-ChtIII showed a strong binding affinity to the regenerated chitin gel column. The apparent molecular weight of PL-ChtIII was estimated to be 29 kDa on SDS-PAGE gel, while its optimum pH and temperature were shown to be pH 6.0 and 60℃, respectively. Analyzing the reaction products of PL-ChtIII with swollen chitin as substrate, the dimer and tetramer of N-acetylglucosamine were produced as major products in the first hour of the enzymatic reaction along with a small amount of monomers and trimers. As the reaction time increased, dimeric N-acetylglucosamine became the predominant form of reaction product.
Lee, Sung-Eun,Choi, Kyungmee,Han, Seunghoon,Lee, Jongtae,Hong, Taegon,Park, Gab-Jin,Yim, Dong-Seok,Min, Chang-Ki RAPID COMMUNICATIONS OF OXFORD LTD 2017 ANTICANCER DRUGS Vol.28 No.6
<P>The usefulness of pharmacokinetics of bortezomib for multiple myeloma (MM) with respect to the maximum response to bortezomib and bortezomib-induced peripheral neuropathy (BIPN) development was studied. Maximum response to subcutaneous bortezomib therapy and BIPN occurrence for the first 12 weeks of treatment in 35 MM patients treated by bortezomib-dexamethasone (VD) and bortezomib-melphalan-prednisone (VMP) were evaluated. On day 1 of cycle 1, seven whole-blood samples were collected for 3 h after dosing completion to obtain the maximum plasma concentration and area under the time-concentration curve during 3 h postdose (AUC(0-3)) in each patient. A total of 35 patients with complete data were analyzed and the overall response rate was 91.4%. Complete response (CR) was observed in 42.9% patients. The maximum plasma concentration (C-max) was significant for the CR rate in two different models [full model: odds ratio (OR) = 1.092; P = 0.038, final model: OR = 1.081; P = 0.038]. In addition, C-max was associated with a progression-free survival advantage. Overall, 48.6% of patients developed BIPN including peripheral sensory neuropathy and neuralgia. The VMP-treated patients had a higher risk compared with the VD-treated patients (OR = 21.662; P = 0.029). C-max had a tendency to affect the occurrence of BIPN (>= grade 2) (OR = 1.064; P = 0.092). In real-world clinical practice using bortezomib for MM patients, C-max among pharmacokinetic factors significantly affected the achievement of CR. The VMP-treated patients showed vulnerability to BIPN, suggesting the necessity for more careful monitoring. Copyright (C) 2017 Wolters Kluwer Health, Inc. All rights reserved.</P>
( Sang Gyune Kim ),( Jeong-ju Yoo ),( Young Seok Kim ),( Bora Lee ),( Soung Won Jeong ),( Jae Young Jang ),( Sae Hwan Lee ),( Hong Soo Kim ),( Young Don Kim ),( Gab Jin Cheon ),( Boo Sung Kim ) 대한간학회 2016 춘·추계 학술대회 (KASL) Vol.2016 No.1
Aims: Non-selective beta-blocker (NSBB) use has been established in the primary and secondary prevention of esophageal variceal hemorrhage. However, the use of beta-blockers in cirrhotic patients with ascites is still under debate. In this study, we compared overall survival (OS) in cirrhotic patients with ascites (≥grade 2) and esophageal varices according to their treatment strategies between endoscopic band ligation (EBL) and NSBB. Methods: This retrospective study included consecutive 269 patients who were diagnosed as liver cirrhosis complicated with esophageal varices and ascites (≥grade 2) in a tertiary single center in Korea. Patients were divided into 3 groups which were EBL only, NSBB, non-treatment group. A Cox-proportional hazard analysis was performed to compare overall survival between the groups. Results: The mean age was 53.8±10.9 years, and median follow-up duration was 37.7 months (IQR, 12.4-65.2). Overall survival was significantly shorter in the NSBB group followed by non-treatment group and EBL only group (median, 47.5 vs. 61.1 vs. 77.0 months; P=0.003). A multivariate analysis showed that the use of NSBB were an independent poor prognostic factor for shorter overall survival (adjusted hazard ratio, 1.98; 95% confidence interval, 1.31-2.98; P<0.001) after adjusted by Child-Pugh class. Conclusions: The use of NSBB worsens the prognosis of cirrhotic patients patients with significant ascites. These results suggest that EBL is a more appropriate treatment option of esophageal varices when complicated with ascites (≥grade 2).